CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 320 · Search date 2026-07-11 · Methodology v0.6

American skullcap,
does it really help with Relief of anxiety and tension?

30-Second Summary
C
Evidence Grade C · 40 · Safety caution
American skullcap has selected mood signals, but anxiety relief is inconsistent in small trials
What the
research shows
Two small double-blind studies in healthy volunteers exist, but the between-group result on the Beck Anxiety Inventory was null in a 43-person crossover trial published in 2014, and its mood signal was limited by carryover and low baseline anxiety. There is no repeated validation in patients with clinical anxiety disorders, resulting in C.
What the
ads claim
Product descriptions may extend traditional calming use and a mood-scale signal in healthy volunteers to treatment of anxiety disorders, immediate sedation, or improved sleep. Direct evidence comes from short studies in healthy volunteers.
*

Useful facts when choosing a product

  • The 2014 trial used S. lateriflora 350 mg three times daily for two weeks per period.
  • American skullcap is a different species from Chinese skullcap, Scutellaria baicalensis.
  • Commercial products have a history of substitution with other skullcap species or adulteration with potentially hepatotoxic germander.
  • Reports of skullcap-associated liver injury often involve mixtures and species-identity problems, leaving the magnitude of risk from authentic S. lateriflora uncertain.
Gap Measurement · Verdict 320 · C 40
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2003 double-blind placebo-controlled crossover study by Wolfson and Hoffmann reported an anxiolytic effect in healthy volunteers, but the PubMed abstract does not provide adequate sample-size and numerical details. The 2014 trial by Brock and colleagues randomized 43 healthy participants to sequences of skullcap 350 mg three times daily and placebo for two weeks each. The between-group BAI difference was not significant (p=0.191), while total mood disturbance improved but interpretation was limited by carryover, low baseline anxiety, and baseline imbalance between groups.

02

Why this is classified as C (40)

Only two small controlled studies in healthy volunteers are available, the primary BAI result in the better-described study was null, and carryover and baseline imbalance limit the positive mood result. With no repeated clinical-anxiety evidence, the rating is at the bottom of C with 40 points.

Counterpoint. Improvement in total mood disturbance and the early anxiolytic signal remain. This judgment does not extend to treatment of diagnosed anxiety disorders or to other Scutellaria species.

Rejudgment record. Reassessment (cross-check reflected) — Only two small double-blind studies in healthy volunteers are available, the between-group BAI result in the 43-person later trial was null, and the positive mood result is limited by carryover and baseline imbalance

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Wolfson P, Hoffmann DL. 2003Double-blind placebo-controlled crossover trialAuthor affiliated with Phytos Inc.Anxiety scaleReported an anxiolytic effect, but numerical and methodological details in the public abstract are limited.Supportive
Brock C et al. 2014Randomized double-blind placebo-controlled crossover trial2UnknownBAI, total mood disturbance, energy, and cognitionThe between-group BAI result was null; total mood disturbance improved, but carryover and baseline imbalance were present.Key
Brock C et al. 2013Botanical identity and compositional analysis of commercial materialUnknownSpecies identity and flavonoid fingerprintDescribed a history of substitution with other skullcap species and adulteration with germander as safety and reproducibility concerns.Safety
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Wolfson P, Hoffmann DL. 2003. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Alternative Therapies in Health and Medicine. 9(2):74-78. PMID: 12652886.
checked
Brock C, Whitehouse J, Tewfik I, Towell T. 2014. American Skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers. Phytotherapy Research. 28(5):692-698. PMID: 23878109. DOI: 10.1002/ptr.5044.
checked
Brock C, Whitehouse J, Tewfik I, Towell T. 2013. Identity issues surrounding American skullcap (Scutellaria lateriflora) and an optimised high performance liquid chromatography method to authenticate commercially available products. Journal of Herbal Medicine. 3(2):57-64. DOI: 10.1016/j.hermed.2013.02.001.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

American skullcap (Scutellaria lateriflora) × Relief of anxiety and tension Evidence Grade C card
[Chamgap] American skullcap (Scutellaria lateriflora) × Relief of anxiety and tension — Evidence Grade C·40. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/mood/american-skullcap-anxiety-tension/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.